Skip to main content

23-10-2023 | Thyroid Cancer | Editor's Choice | News

Phase 3 data support first-line use of selpercatinib for RET-mutant medullary thyroid cancer

Author: Dr. Shreeya Nanda

medwireNews: The phase 3 LIBRETTO-531 trial has demonstrated the superiority of selpercatinib, a highly selective RET kinase inhibitor, over approved multikinase inhibitors in people with advanced RET-mutant medullary thyroid cancer.

Related topics

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare